Canadian Sec - Delayed Quote CAD

PharmaTher Holdings Ltd. (PHRM.CN)

0.2150

-0.0150

(-6.52%)

At close: January 10 at 12:21:59 PM EST

PharmaTher CEO Issues Letter to Shareholders

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the development and commercialization of ketamine, announced today that Fabio Chianelli, the Company’s Chairman and Chief Executive Officer, has issued the following letter to shareholders. Dear Fellow Shareholders: With the start of a new year, I sincerely thank our loyal shareholders for your continued patience, confidence

GlobeNewswire 4 days ago

PHRRF
+6.67%
PharmaTher Announces Grant of Stock Options

TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that it has granted a total of 800,000 stock options to two of the three directors of the Company at an exercise price of $0.22 per share. The stock options vest immediately on the grant date and have a five-year term, expiring January 2, 2030. The Chairman and CEO, Fabio Chianelli, did not receive stock options. About Pharm

GlobeNewswire 7 days ago

PHRRF
+6.67%
3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

As the Canadian market maintains strong momentum heading into 2025, investors are advised to be mindful of potential curveballs despite the optimism surrounding solid fundamentals and rising corporate profits. In this context, penny stocks—though an outdated term—continue to represent an intriguing investment area for those interested in smaller or less-established companies. By focusing on stocks with robust financials and a clear growth trajectory, investors may uncover opportunities that...

Simply Wall St. last month

TTSRF

PHRRF
+6.67%
QIPT
PharmaTher Announces Update on FDA New Drug Application for Ketamine

FDA provided preliminary responses to questions contained in the clarification only post-CRL meeting scheduled for December 2, 2024 PharmaTher has decided to cancel the meeting as the FDA preliminary responses were satisfactory and do not require further discussion PharmaTher initiated activities to address the MINOR deficiencies cited in the CRL TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceuti

GlobeNewswire last month

PHRRF
+6.67%
PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company requested a post-complete letter clarification meeting (the “Meeting”) in response to the FDA issuing a complete response letter (CRL), dated October 22, 2024, for the ketamine Abbreviated New Drug Application, which was assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of October

GlobeNewswire last month

PHRRF
+6.67%
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, “Neuroprotective effects of psiloc

GlobeNewswire last month

RVVTF

PHRRF
+6.67%
PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

TORONTO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL), dated October 22, 2024, for the ketamine Abbreviated New Drug Application, which was assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of October 29, 2024. The deficiencies cited in the CRL are classified

GlobeNewswire 2 months ago

PHRRF
+6.67%
TSX Penny Stocks To Consider In October 2024

The Canadian market has seen a notable upswing, with a 1.0% increase over the last week and an impressive 27% rise in the past year, alongside forecasts of annual earnings growth at 16%. In light of these conditions, identifying stocks with strong fundamentals becomes crucial for investors seeking potential growth opportunities. Penny stocks may be considered a dated term, but they continue to represent viable investment options by offering access to smaller or newer companies that could...

Simply Wall St. 2 months ago

BENZF

AZASF

PHRRF
+6.67%
PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - PharmaDrug Inc. (CSE: PHRX) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and previously approved drugs, is pleased to announce its strategic plans to advance the clinical development of its patented enteric-coated Cepharanthine formulation ("PD-001") for viral infectious diseases.

Newsfile 4 months ago

LMLLF

PHRRF
+6.67%
PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins

TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF), announced today that an independent screening of drugs for monkeypox (“Mpox”) highlighted cepharanthine’s potential to bind to the viru

GlobeNewswire 4 months ago

PHRRF
+6.67%
LMLLF
PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

TORONTO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug"), has received approval by the Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical s

GlobeNewswire 4 months ago

LMLLF

PHRRF
+6.67%
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug"), has submitted to the Australian Human Research Ethics Committee for review and potential approval to initiate a Phase 1

GlobeNewswire 7 months ago

PHRRF
+6.67%
LMLLF
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

The FDA Assigned Goal Date is October 29, 2024TORONTO, May 10, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of an Amendment Acknowledgment Letter (“AAL”) for its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine from the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of Octobe

GlobeNewswire 7 months ago

PHRRF
+6.67%
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

TORONTO, May 01, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug”), has completed its clinical and regulatory package to evaluate Sairiyo’s patented reformulated enteric coated version of

GlobeNewswire 8 months ago

LMLLF

PHRRF
+6.67%
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced receipt of a Complete Response Letter (“CRL”) for its Priority Original Abbreviated New Drug Application (“ANDA”) for Ketamine that was accepted by the U.S. Food and Drug Administration (the “FDA”) and assigned a Generic Drug User Fee Amendments of 2022 (“GDUFA”) goal date of April 29, 2024. The CRL is similar to the

GlobeNewswire 8 months ago

PHRRF
+6.67%
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s clinical study (the “Study”) (NCT05322954) evaluating the safety and feasibility of oral psilocybin as a potential treatment for methamphetamine use disorder conducted under an invest

GlobeNewswire 9 months ago

RVVTF

PHRRF
+6.67%
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announced today Sairiyo Therapeutics Inc. (“Sairiyo”), a company that is forty-nine percent (49%) owned by PharmaTher and fifty-one percent (51%) owned by PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug”), has initiated its regulatory and clinical development plan to evaluate Sairiyo’s patented reformulated enteric coated v

GlobeNewswire 10 months ago

PHRRF
+6.67%
LMLLF
Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Key Takeaways; Psychedelic Sector Two weeks into the new year, the cannabis sector is buzzing with anticipation as a recent unredacted exchange among federal authorities revealed a compelling catalyst for a potential rally. The released documents from the Health and Human Services disclosed that federal scientists are recommending the removal of […]

Market Exclusive 11 months ago

CGC

PHRRF
+6.67%
FFNTF

Performance Overview

Return	PHRM.CN	S&P/TSX Composite index
YTD	-8.51%	+0.60%
1-Year	-4.44%	+18.10%
3-Year	-43.42%	+17.47%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PharmaTher Holdings Ltd. (PHRM.CN)

PharmaTher CEO Issues Letter to Shareholders

PharmaTher Announces Grant of Stock Options

3 TSX Penny Stocks With Market Caps Over CA$20M To Watch

PharmaTher Announces Update on FDA New Drug Application for Ketamine

PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

PharmaTher Receives Complete Response Letter from the U.S. Food and Drug Administration for Ketamine Abbreviated New Drug Application

TSX Penny Stocks To Consider In October 2024

PharmaDrug's Sairiyo Therapuetics Provides Strategic Plans to Advance PD-001 (Patented Reformulated Cepharanthine) for Viral Infectious Diseases

PharmaTher’s Sairiyo Therapeutics Announces Independent Screening Identifying Cepharanthine’s Potential to Bind to Monkeypox (Mpox) Proteins

PharmaTher’s Sairiyo Therapeutics Receives Approval to Initiate a Phase 1 Human Clinical Trial of PD-001 (Reformulated Cepharanthine)

PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine

PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine

PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine

Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder

PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Performance Overview